Moleculin nearing pivotal AML trial data readout, unblinding expected before June 30

Filed May 13, 2026 · Period ending May 13, 2026 · ~1 min read

Key Changes

• high

  First data unblinding from Phase 2B/3 MIRACLE trial testing Annamycin for relapsed/refractory acute myeloid leukemia expected before June 30, 2026, reaffirming prior timeline.

  Item 7.01 verify on EDGAR →
• medium

  Trial compares two dose levels of Annamycin plus cytarabine against placebo plus cytarabine in patients who failed initial AML treatment.

  Press Release verify on EDGAR →